Santhera Pharmaceuticals (SIX: SANN) has released preliminary, unaudited key financial figures for 2016.
The Swiss drugmaker has reported net revenue of 19 million Swiss francs ($19 million) for the year, four times higher than the previous year. Sales in the second half of 2016 were 64% higher than in the first six months.
Cash and cash equivalents were just shy of 50 million francs ($50 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze